secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0001558370-22-009976
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 3.02, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage issues $4M Series E Convertible Preferred to Harvard Bioscience to satisfy indemnification
--------------------------------------------------------------------------------

- Issued 4,000 shares of Series E Preferred at $1,000/share to HBIO on June 10, 2022, to settle $4M indemnification obligations.
- 8% annual dividend payable quarterly in additional Series E shares; ranks senior to common stock.
- Mandatory conversion upon NASDAQ uplisting, IPO, or $4M+ private placement; optional conversion based on 60-day VWAP.
- Consent rights restrict debt over $500K, certain related-party transactions, and issuance of senior or pari passu securities.
- Beneficial ownership limitation capped at 9.99% on conversion; limited piggyback registration rights if Rule 144 unavailable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000155837022009976/0001558370-22-009976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000155837022009976/tmb-20220610x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-009976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer